2023
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma
Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.Peer-Reviewed Original ResearchConceptsMedian overall survivalProgression-free survivalOverall survivalRecurrent glioblastomaAdverse eventsTherapy groupMedian progression-free survivalDevice-related adverse eventsSafety/feasibilitySerious adverse eventsFurther prospective studiesConcurrent therapyInvestigator's discretionStandard chemotherapyProspective studyTRIAL REGISTRATIONPatientsMonthsTreatmentHome-use deviceGlioblastomaWeeksSurvivalTotalGroup
2021
QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS
Blondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.Peer-Reviewed Original ResearchMalignant glioma patientsMedical marijuana programMalignant gliomasInactive patientsCannabis therapyActive patientsComplementary therapiesGlioma patientsOil supplementsCannabis productsMedian overall survivalSignificant palliative benefitSerious adverse eventsOverall survivalAdverse eventsDaily groupPalliative benefitCannabis treatmentPatientsPatient registration processOil groupTherapyGliomasMonthsSurvival
2019
ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.Peer-Reviewed Original ResearchSerious adverse eventsAdverse eventsRecurrent glioblastomaOverall survivalOutcome measuresDevice-related serious adverse eventsMedian overall survivalProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureLong-term treatmentMulti-center studyAnti-cancer therapyProspective studyTreatment groupsFeasible treatmentPatientsBrain cancerInvestigator's choiceInvestigational deviceChemotherapyGlioblastomaMonthsTreatmentACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.Peer-Reviewed Original ResearchAdverse eventsOutcome measuresDevice-related serious adverse eventsSerious adverse eventsProgression-free survivalSecondary outcome measuresCessation of treatmentFurther prospective studiesPrimary outcome measureStandard of careMulti-center studyMild dysesthesiaSurgical debulkingOverall survivalProspective studyClinical utilityFeasible treatmentPatientsBrain cancerInvestigational deviceMonthsTreatmentGBMSurvivalDebulking
2018
QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT
Blondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT. Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.Peer-Reviewed Original ResearchOverall survivalCannabis therapyTherapeutic cannabisPalliative useMedian ageCare treatmentGBM patientsSignificant adverse eventsTime period 2Time period 1Diagnosis dateAdverse eventsPatient ageSurvival benefitTumor characteristicsTherapeutic roleTreatment strategiesPatientsAnimal modelsHuman patientsGlioblastoma treatmentTherapeutic treatmentCannabis useTherapyGlioblastomaACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.Peer-Reviewed Original ResearchDevice-related adverse eventsAdverse eventsOutcome measuresMaximal tumor debulkingSecond-line therapyProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureStandard of careMulti-center trialInvestigational medical deviceTreatment of glioblastomaClinical utility dataContinual therapyConcurrent therapyOverall survivalProspective studySafety profileTumor debulkingInterim safetyClinical utilityFeasible treatmentPatientsBrain cancerHOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL
Blondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.Peer-Reviewed Original ResearchQuality-adjusted life yearsHealth utility valuesLong-term survivorsLong-term survivalHealth utilityCondition-specific questionnaireEF-14 trialQuality of lifeHealth economic evaluationsGeneral population sampleStable diseaseAdverse eventsPreference-based measuresMultiple myelomaGBM patientsHealth state scenariosGlioblastoma patientsPatientsGBM treatmentSurvival rateLife yearsNew treatmentsUtility valuesDiagnosisHealth Panel